Skip to content

The role of anti - miasmatic homoeopathic medicines in the treatment of breathing difficulty

The Effectiveness of Anti-miasmatic Management of Bronchial Asthma using Asthma Control Test Assessment criteria – A Prospective Study - NIL

Status
Active, not recruiting
Phases
Phase 3Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/06/069367
Enrollment
30
Registered
2024-06-21
Start date
Unknown
Completion date
Unknown
Last updated
2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J459- Other and unspecified asthma

Interventions

Intervention1: Anti - Miasmatic Homoeopathic Medicine: Case Taking will be done and the most suitable anti - miasmatic homoeopathic medicine selected based on totality of symptoms will be prescribed.

Sponsors

Sarada Krishna Homoeopathic Medical College
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patient having symptoms of Bronchial Asthma such as dyspnea, expiratory wheeze, cough and tightness of chest.

Exclusion criteria

Exclusion criteria: Pregnant and Lactating women. Patients with other co-morbidities such as hypertension, diabetes mellitus, dyslipidemia, hyperthyroidism, hypothyroidism, etc. Patients with complications of Bronchial Asthma such as Frequent respiratory infections, Pulmonary collapse, Respiratory failure, Pneumothorax, Cor pulmonale and Allergic bronchopulmonary aspergillosis.

Design outcomes

Primary

MeasureTime frame
Analyzing the severity of symptoms in cases diagnosed with Bronchial asthma before medication.Timepoint: 9 MONTHS

Secondary

MeasureTime frame
Symptomatic and general improvement in the condition of patients through evaluation using assessment tool.Timepoint: 9 MONTHS

Countries

India

Contacts

Public ContactDr M Murugan

Sarada Krishna Homoeopathic Medical College

drmmuruganhomoeo@gmail.com9443343707

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026